Our FY2018 Financial report is available on the following LINK, but we would like to take advantage of our Newsletter to share with you the most relevant facts of it:
- Werfen maintaining leadership position in our target IVD markets
- Turnover of 1,359 million euros that represents 5,3 % vs PY
- TEM & Accriva acquisitions successfully integrated into Werfen
- Continuous commitment on R&D to assure our long term successful
- Our Werfen values as pillars of our goals and aspirations to enhance the level of care
|
Let me finish this brief introduction with words of our President Marc Rubiralta:
“We will continue to achieve this by putting patients at the centre of what we do, investing in innovation”.
Good reading!
Pepe Zamora (EEMEAI Director)
Last modified on Tuesday, 31 May 2022 12:51